Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 79 | 2023 | 20774 | 2.330 |
Why?
|
Receptors, Progesterone | 12 | 2018 | 1097 | 0.950 |
Why?
|
Postmenopause | 14 | 2022 | 2461 | 0.850 |
Why?
|
Estrogen Replacement Therapy | 7 | 2013 | 1202 | 0.850 |
Why?
|
Nurses | 14 | 2023 | 2459 | 0.760 |
Why?
|
Premenopause | 14 | 2018 | 1033 | 0.720 |
Why?
|
Carcinoma, Ductal, Breast | 5 | 2016 | 1101 | 0.660 |
Why?
|
Receptors, Estrogen | 13 | 2022 | 2186 | 0.650 |
Why?
|
Aspirin | 6 | 2019 | 3278 | 0.640 |
Why?
|
Amino Acids, Essential | 1 | 2016 | 24 | 0.580 |
Why?
|
Dietary Proteins | 3 | 2016 | 963 | 0.500 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2016 | 249 | 0.480 |
Why?
|
Hot Flashes | 1 | 2014 | 316 | 0.400 |
Why?
|
Alcohol Drinking | 6 | 2015 | 3957 | 0.390 |
Why?
|
Hormone Replacement Therapy | 2 | 2008 | 744 | 0.380 |
Why?
|
Uridine Diphosphate N-Acetylglucosamine | 1 | 2009 | 17 | 0.350 |
Why?
|
Streptococcus equi | 1 | 2009 | 9 | 0.350 |
Why?
|
Breast | 2 | 2017 | 1958 | 0.350 |
Why?
|
Risk Factors | 45 | 2022 | 72145 | 0.330 |
Why?
|
Melatonin | 1 | 2014 | 720 | 0.320 |
Why?
|
Dietary Fiber | 4 | 2016 | 760 | 0.320 |
Why?
|
Nutritional Status | 1 | 2016 | 1606 | 0.320 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 947 | 0.310 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2013 | 1239 | 0.300 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2007 | 129 | 0.290 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 1517 | 0.280 |
Why?
|
Affect | 1 | 2014 | 1473 | 0.270 |
Why?
|
Female | 84 | 2023 | 379592 | 0.270 |
Why?
|
Neoplasm Metastasis | 5 | 2021 | 4839 | 0.270 |
Why?
|
Hyaluronic Acid | 1 | 2009 | 489 | 0.270 |
Why?
|
Ethanol | 1 | 2011 | 1337 | 0.250 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2014 | 997 | 0.250 |
Why?
|
Proportional Hazards Models | 17 | 2020 | 12344 | 0.250 |
Why?
|
Menopause, Premature | 1 | 2006 | 132 | 0.250 |
Why?
|
Endocrinology | 1 | 2011 | 443 | 0.250 |
Why?
|
Fruit | 3 | 2020 | 1139 | 0.250 |
Why?
|
Vegetables | 3 | 2020 | 1179 | 0.250 |
Why?
|
Mammography | 1 | 2015 | 2474 | 0.250 |
Why?
|
Gonadal Steroid Hormones | 1 | 2008 | 711 | 0.240 |
Why?
|
Carcinoma, Lobular | 3 | 2016 | 484 | 0.240 |
Why?
|
Feeding Behavior | 6 | 2018 | 3187 | 0.240 |
Why?
|
Prospective Studies | 30 | 2023 | 53187 | 0.220 |
Why?
|
Receptors, Calcitriol | 1 | 2005 | 350 | 0.220 |
Why?
|
Central Nervous System Stimulants | 1 | 2011 | 1148 | 0.220 |
Why?
|
Risk Assessment | 18 | 2017 | 23320 | 0.220 |
Why?
|
Dietary Fats | 4 | 2014 | 2017 | 0.220 |
Why?
|
Tamoxifen | 1 | 2007 | 980 | 0.210 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.210 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2006 | 627 | 0.210 |
Why?
|
Women's Health | 3 | 2020 | 2034 | 0.210 |
Why?
|
Dietary Supplements | 2 | 2020 | 3294 | 0.200 |
Why?
|
Middle Aged | 49 | 2021 | 213127 | 0.200 |
Why?
|
Ovary | 1 | 2006 | 981 | 0.200 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3070 | 0.200 |
Why?
|
Smoking | 6 | 2013 | 8969 | 0.200 |
Why?
|
Adult | 54 | 2021 | 213712 | 0.200 |
Why?
|
Nitriles | 2 | 2021 | 952 | 0.200 |
Why?
|
Meningeal Carcinomatosis | 1 | 2021 | 65 | 0.190 |
Why?
|
Humans | 85 | 2023 | 742088 | 0.190 |
Why?
|
Odds Ratio | 6 | 2016 | 9846 | 0.190 |
Why?
|
Estrogens | 4 | 2011 | 1562 | 0.190 |
Why?
|
Aromatase Inhibitors | 1 | 2004 | 491 | 0.180 |
Why?
|
Incidence | 16 | 2018 | 20928 | 0.180 |
Why?
|
Hyperinsulinism | 1 | 2022 | 415 | 0.170 |
Why?
|
Carcinoma | 1 | 2011 | 2374 | 0.170 |
Why?
|
Neoplasm Staging | 9 | 2020 | 11001 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2017 | 9185 | 0.170 |
Why?
|
Genes, BRCA2 | 1 | 2002 | 617 | 0.170 |
Why?
|
Meat | 3 | 2014 | 595 | 0.170 |
Why?
|
Receptor, erbB-2 | 6 | 2021 | 2410 | 0.170 |
Why?
|
Fatigue | 2 | 2023 | 1526 | 0.170 |
Why?
|
Genes, BRCA1 | 1 | 2002 | 780 | 0.160 |
Why?
|
Dietary Carbohydrates | 3 | 2020 | 904 | 0.160 |
Why?
|
Triazoles | 1 | 2004 | 907 | 0.160 |
Why?
|
Meningeal Neoplasms | 2 | 2021 | 1241 | 0.160 |
Why?
|
Diet | 7 | 2022 | 7923 | 0.150 |
Why?
|
Paclitaxel | 2 | 2022 | 1707 | 0.150 |
Why?
|
Multivariate Analysis | 8 | 2016 | 12242 | 0.140 |
Why?
|
Aged | 25 | 2023 | 162944 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 11472 | 0.130 |
Why?
|
Dairy Products | 2 | 2018 | 498 | 0.130 |
Why?
|
Cholecalciferol | 1 | 2020 | 537 | 0.130 |
Why?
|
Blood Platelets | 2 | 2019 | 2506 | 0.130 |
Why?
|
Confidence Intervals | 5 | 2020 | 2970 | 0.130 |
Why?
|
Leucine | 1 | 2016 | 560 | 0.130 |
Why?
|
Survivors | 3 | 2014 | 2286 | 0.120 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2007 | 414 | 0.120 |
Why?
|
Glycemic Index | 3 | 2020 | 395 | 0.110 |
Why?
|
United States | 17 | 2018 | 69693 | 0.110 |
Why?
|
Fibrocystic Breast Disease | 1 | 2013 | 102 | 0.110 |
Why?
|
Survival Analysis | 6 | 2021 | 10248 | 0.110 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 3800 | 0.110 |
Why?
|
Prognosis | 8 | 2022 | 29010 | 0.110 |
Why?
|
Vitamins | 1 | 2020 | 1608 | 0.100 |
Why?
|
Weight Gain | 2 | 2017 | 2282 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2938 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1788 | 0.100 |
Why?
|
Models, Statistical | 4 | 2019 | 5100 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2012 | 15494 | 0.100 |
Why?
|
Menarche | 1 | 2013 | 513 | 0.090 |
Why?
|
Echocardiography | 1 | 2023 | 5097 | 0.090 |
Why?
|
Follow-Up Studies | 12 | 2018 | 39004 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 1970 | 0.090 |
Why?
|
Dissent and Disputes | 1 | 2011 | 138 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1713 | 0.090 |
Why?
|
Mathematical Computing | 2 | 2007 | 147 | 0.090 |
Why?
|
Nisin | 1 | 2009 | 4 | 0.090 |
Why?
|
Time Factors | 10 | 2017 | 40054 | 0.090 |
Why?
|
Genetic Testing | 1 | 2002 | 3439 | 0.090 |
Why?
|
Intracranial Embolism | 1 | 2011 | 202 | 0.090 |
Why?
|
ABO Blood-Group System | 1 | 2012 | 367 | 0.090 |
Why?
|
Lactococcus lactis | 1 | 2009 | 28 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 2276 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2022 | 3861 | 0.080 |
Why?
|
Acrylamide | 1 | 2009 | 60 | 0.080 |
Why?
|
Glucuronosyltransferase | 1 | 2009 | 128 | 0.080 |
Why?
|
Nausea | 2 | 2022 | 665 | 0.080 |
Why?
|
Cyclooxygenase 2 | 1 | 2011 | 611 | 0.080 |
Why?
|
Quinazolines | 2 | 2012 | 1355 | 0.080 |
Why?
|
Endometriosis | 1 | 2016 | 834 | 0.080 |
Why?
|
Operon | 1 | 2009 | 360 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2011 | 13655 | 0.080 |
Why?
|
Microbiological Techniques | 1 | 2009 | 102 | 0.080 |
Why?
|
Research | 1 | 2017 | 1999 | 0.080 |
Why?
|
Anticarcinogenic Agents | 1 | 2010 | 253 | 0.080 |
Why?
|
Cause of Death | 2 | 2020 | 3571 | 0.080 |
Why?
|
Age Factors | 7 | 2017 | 18355 | 0.080 |
Why?
|
Alanine | 1 | 2009 | 572 | 0.070 |
Why?
|
Life Style | 3 | 2008 | 3824 | 0.070 |
Why?
|
Endocarditis | 1 | 2011 | 348 | 0.070 |
Why?
|
Diabetes, Gestational | 1 | 2016 | 1184 | 0.070 |
Why?
|
Molecular Weight | 1 | 2009 | 2255 | 0.070 |
Why?
|
Lymphatic Metastasis | 3 | 2011 | 2906 | 0.070 |
Why?
|
Carcinogens | 1 | 2009 | 466 | 0.070 |
Why?
|
Glycine | 1 | 2009 | 671 | 0.070 |
Why?
|
Dihydroxycholecalciferols | 1 | 2005 | 17 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2019 | 3067 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6534 | 0.070 |
Why?
|
Forecasting | 1 | 2015 | 2948 | 0.070 |
Why?
|
Progesterone | 2 | 2017 | 773 | 0.070 |
Why?
|
Case-Control Studies | 5 | 2016 | 21719 | 0.070 |
Why?
|
Vitamin D | 3 | 2018 | 3211 | 0.070 |
Why?
|
Physical Endurance | 1 | 2008 | 370 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2016 | 2896 | 0.060 |
Why?
|
Genotype | 3 | 2012 | 12946 | 0.060 |
Why?
|
Counseling | 2 | 2004 | 1521 | 0.060 |
Why?
|
Nutrition Assessment | 2 | 2018 | 723 | 0.060 |
Why?
|
Exercise | 3 | 2008 | 5611 | 0.060 |
Why?
|
Physical Fitness | 1 | 2009 | 732 | 0.060 |
Why?
|
Adolescent | 10 | 2022 | 85649 | 0.060 |
Why?
|
Acetaminophen | 1 | 2009 | 544 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2020 | 12017 | 0.060 |
Why?
|
Genital Neoplasms, Female | 1 | 2010 | 516 | 0.060 |
Why?
|
Neoplasms | 2 | 2020 | 21596 | 0.060 |
Why?
|
Laparoscopy | 1 | 2016 | 2121 | 0.060 |
Why?
|
Risk | 5 | 2016 | 9679 | 0.060 |
Why?
|
Piperidines | 1 | 2012 | 1602 | 0.060 |
Why?
|
Disease Progression | 2 | 2020 | 13256 | 0.060 |
Why?
|
Plasmids | 1 | 2009 | 2305 | 0.060 |
Why?
|
Energy Intake | 2 | 2022 | 2147 | 0.060 |
Why?
|
Muscle Strength | 1 | 2008 | 586 | 0.060 |
Why?
|
Body Mass Index | 8 | 2015 | 12695 | 0.060 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2009 | 1119 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2013 | 1952 | 0.050 |
Why?
|
Cyclophosphamide | 2 | 2022 | 2236 | 0.050 |
Why?
|
Environmental Monitoring | 1 | 2009 | 1413 | 0.050 |
Why?
|
Plant Oils | 1 | 2023 | 202 | 0.050 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3612 | 0.050 |
Why?
|
Consensus | 1 | 2011 | 2935 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2017 | 57683 | 0.050 |
Why?
|
Parity | 2 | 2016 | 929 | 0.050 |
Why?
|
Recurrence | 1 | 2013 | 8333 | 0.050 |
Why?
|
Sleep | 1 | 2017 | 4604 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 159 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3239 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2021 | 8829 | 0.050 |
Why?
|
Carotenoids | 1 | 2003 | 624 | 0.050 |
Why?
|
Body Weight | 3 | 2008 | 4664 | 0.050 |
Why?
|
Hysterectomy | 1 | 2006 | 927 | 0.050 |
Why?
|
Vitamin A | 1 | 2003 | 615 | 0.050 |
Why?
|
Ascorbic Acid | 1 | 2003 | 647 | 0.040 |
Why?
|
Insulin | 2 | 2020 | 6575 | 0.040 |
Why?
|
Obesity | 3 | 2020 | 12705 | 0.040 |
Why?
|
Primary Prevention | 1 | 2007 | 1166 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 227 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2006 | 2876 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2009 | 3420 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 799 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 647 | 0.040 |
Why?
|
Longitudinal Studies | 4 | 2020 | 13921 | 0.040 |
Why?
|
Motor Activity | 1 | 2009 | 2714 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6891 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 10943 | 0.040 |
Why?
|
Diet Records | 1 | 2020 | 425 | 0.040 |
Why?
|
Young Adult | 6 | 2016 | 56350 | 0.040 |
Why?
|
Vitamin E | 1 | 2003 | 869 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 665 | 0.040 |
Why?
|
Cohort Studies | 7 | 2022 | 40450 | 0.040 |
Why?
|
Medical History Taking | 1 | 2002 | 783 | 0.040 |
Why?
|
Vomiting | 1 | 2022 | 632 | 0.040 |
Why?
|
Quality of Life | 2 | 2014 | 12730 | 0.040 |
Why?
|
Sweetening Agents | 1 | 2021 | 296 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 890 | 0.040 |
Why?
|
Lactose | 1 | 2018 | 95 | 0.040 |
Why?
|
Health Surveys | 3 | 2017 | 4030 | 0.040 |
Why?
|
Exanthema | 1 | 2021 | 488 | 0.040 |
Why?
|
Blood Glucose | 3 | 2020 | 6249 | 0.040 |
Why?
|
PTEN Phosphohydrolase | 1 | 2022 | 1144 | 0.040 |
Why?
|
Folic Acid | 1 | 2003 | 1300 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 8425 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15530 | 0.030 |
Why?
|
Testosterone | 1 | 2006 | 2401 | 0.030 |
Why?
|
Neovascularization, Pathologic | 2 | 2019 | 2633 | 0.030 |
Why?
|
Dyspnea | 1 | 2023 | 1298 | 0.030 |
Why?
|
Calcium, Dietary | 1 | 2018 | 527 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 5163 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2005 | 4328 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2002 | 1786 | 0.030 |
Why?
|
Depression | 1 | 2014 | 7733 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2009 | 4231 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 7276 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1612 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2022 | 3471 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2066 | 0.030 |
Why?
|
Colitis | 1 | 2021 | 1149 | 0.030 |
Why?
|
Endometrial Neoplasms | 1 | 2003 | 1351 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2023 | 12958 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2017 | 577 | 0.030 |
Why?
|
Platelet Factor 4 | 1 | 2012 | 129 | 0.030 |
Why?
|
Reproductive History | 1 | 2013 | 209 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2022 | 5062 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2018 | 1656 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2004 | 2542 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 162 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10372 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2023 | 77098 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7153 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2502 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2014 | 62966 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 3839 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8297 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 552 | 0.020 |
Why?
|
Overweight | 1 | 2020 | 2366 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 2933 | 0.020 |
Why?
|
Stroke | 1 | 2011 | 9963 | 0.020 |
Why?
|
Research Design | 1 | 2004 | 5979 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2010 | 891 | 0.020 |
Why?
|
Eating | 1 | 2014 | 1535 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2900 | 0.020 |
Why?
|
Adiposity | 1 | 2017 | 1806 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2004 | 9941 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2008 | 517 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2012 | 17400 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1720 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2616 | 0.020 |
Why?
|
Family Health | 1 | 2010 | 1282 | 0.020 |
Why?
|
Tumor Burden | 1 | 2011 | 1905 | 0.020 |
Why?
|
Cytokines | 1 | 2019 | 7317 | 0.010 |
Why?
|
Doxorubicin | 1 | 2010 | 2215 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2010 | 1269 | 0.010 |
Why?
|
Pregnancy | 2 | 2016 | 29087 | 0.010 |
Why?
|
Menopause | 1 | 2010 | 1621 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2699 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16665 | 0.010 |
Why?
|
Causality | 1 | 2009 | 1265 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25575 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3502 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 3915 | 0.010 |
Why?
|
Contraceptives, Oral | 1 | 2003 | 563 | 0.010 |
Why?
|
Nurse Practitioners | 1 | 2004 | 270 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2012 | 8621 | 0.010 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2004 | 395 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3510 | 0.010 |
Why?
|
Sample Size | 1 | 2003 | 844 | 0.010 |
Why?
|
Proteomics | 1 | 2012 | 3618 | 0.010 |
Why?
|
Age of Onset | 1 | 2006 | 3266 | 0.010 |
Why?
|
Diet Surveys | 1 | 2003 | 1172 | 0.010 |
Why?
|
Focus Groups | 1 | 2004 | 1320 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 19862 | 0.010 |
Why?
|
Mutation | 1 | 2023 | 29717 | 0.010 |
Why?
|
Registries | 1 | 2014 | 8077 | 0.010 |
Why?
|
Body Composition | 1 | 2008 | 2400 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9305 | 0.010 |
Why?
|
Massachusetts | 1 | 2009 | 8662 | 0.010 |
Why?
|
Logistic Models | 1 | 2011 | 13403 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 6483 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23387 | 0.010 |
Why?
|
Male | 3 | 2021 | 349538 | 0.010 |
Why?
|
Attitude to Health | 1 | 2004 | 2051 | 0.010 |
Why?
|
Survival Rate | 1 | 2007 | 12773 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 11695 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 3038 | 0.010 |
Why?
|
Animals | 2 | 2014 | 168561 | 0.010 |
Why?
|
Health Behavior | 1 | 2004 | 2630 | 0.010 |
Why?
|
Health Promotion | 1 | 2004 | 2194 | 0.010 |
Why?
|
Internet | 1 | 2004 | 3062 | 0.010 |
Why?
|
Mass Screening | 1 | 2004 | 5238 | 0.000 |
Why?
|
Predictive Value of Tests | 1 | 2004 | 15056 | 0.000 |
Why?
|
Primary Health Care | 1 | 2004 | 4551 | 0.000 |
Why?
|
Physicians | 1 | 2004 | 4554 | 0.000 |
Why?
|
Aging | 1 | 2004 | 8626 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 2007 | 13019 | 0.000 |
Why?
|